B55.9 Leishmaniasis, unspecified

Name of the Condition

• Leishmaniasis, unspecified

Summary

Leishmaniasis, unspecified is a parasitic infection caused by Leishmania protozoa. It is transmitted through the bite of infected sandflies and can present in various clinical forms, including cutaneous, mucocutaneous, or visceral disease. The condition’s severity and manifestations depend on the parasite species and the host’s immune response, ranging from self-resolving skin lesions to life-threatening systemic involvement.

Causes

Leishmaniasis, unspecified is caused by Leishmania parasites transmitted to humans via the bite of infected female sandflies (genus Phlebotomus in the Old World or Lutzomyia in the New World). The parasites enter the skin during feeding, multiply within macrophages, and may disseminate to other tissues, leading to diverse clinical presentations.

Risk Factors

• Exposure to sandfly habitats, such as rural or tropical regions where the insects breed.
• Immunocompromised states, including HIV/AIDS, organ transplantation, or chemotherapy.
• Malnutrition or other conditions that weaken the immune system.
• Travel to or residence in endemic areas, particularly in parts of Asia, Africa, Latin America, and the Mediterranean.

Symptoms

• Cutaneous leishmaniasis: Painless or mildly painful skin ulcers, often with a raised border, that may heal slowly.
• Mucocutaneous leishmaniasis: Lesions affecting mucous membranes (e.g., nose, mouth), potentially causing disfigurement.
• Visceral leishmaniasis: Persistent fever, weight loss, enlarged spleen or liver, and anemia.

Diagnosis

Diagnosis involves clinical evaluation, microscopic examination of tissue samples (e.g., skin scrapings, bone marrow aspirates) for Leishmania parasites, and serological or molecular testing. Imaging or biopsy may be used to assess organ involvement in visceral cases.

Treatment Options

Treatment depends on the disease form and severity. Cutaneous leishmaniasis may resolve without therapy or require topical or systemic antiparasitic medications. Visceral leishmaniasis typically requires intravenous or oral antileishmanial drugs, such as amphotericin B or miltefosine. Supportive care addresses complications like anemia or organ dysfunction.

Prognosis and Follow-Up

Prognosis varies by disease type: cutaneous leishmaniasis often has a good outcome with treatment, while visceral leishmaniasis can be fatal if untreated. Follow-up includes monitoring for treatment response, recurrence, or progression to other forms, especially in immunocompromised patients.

Complications

• Disfigurement from mucocutaneous lesions.
• Organ damage (e.g., splenomegaly, hepatomegaly) in visceral disease.
• Secondary infections in skin ulcers.
• Increased mortality in untreated or severe cases.

Lifestyle & Prevention

• Avoid sandfly bites by using insect repellent, wearing protective clothing, and sleeping under insecticide-treated nets.
• Minimize exposure in endemic areas, especially during peak sandfly activity (dusk to dawn).
• Prompt treatment of skin lesions to prevent dissemination.

When to Seek Professional Help

Seek care if you develop unexplained skin ulcers, persistent fever, weight loss, or organ enlargement after travel to endemic regions. Early diagnosis improves outcomes, particularly for visceral leishmaniasis.

Tips for Medical Coders

Use B55.9 for cases of leishmaniasis where the specific type (cutaneous, mucocutaneous, or visceral) is not documented. Document the clinical presentation and any available test results to support the unspecified diagnosis. Ensure alignment with clinical notes to confirm the absence of more specific details.